First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
Author:
Funder
Janssen Pharmaceuticals
Celgene
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Link
http://www.nature.com/articles/s41408-021-00415-5.pdf
Reference14 articles.
1. van de Donk, N. W., Lokhorst, H. M., Anderson, K. C. & Richardson, P. G. How I treat plasma cell leukemia. Blood 120, 2376–2389 (2012).
2. Katodritou, E. et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am. J. Hematol. 89, 145–150 (2014).
3. Gavriatopoulou, M. et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 32, 1883–1898 (2018).
4. Gonsalves, W. I. et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 124, 907–912 (2014).
5. Katodritou, E. et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Blood Cancer J. 8, 31 (2018).
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression;Leukemia & Lymphoma;2024-08
2. Monoclonal Antibodies in the Treatment of Multiple Myeloma;Hematology/Oncology Clinics of North America;2023-12
3. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study;The Lancet Oncology;2023-10
4. Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group;Leukemia & Lymphoma;2023-01-25
5. Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy;Frontiers in Oncology;2022-09-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3